MedTrace Logo

Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

NCT06868732 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 288

Last updated 2026-03-30

No results posted yet for this study

Summary

This is a Phase Ib clinical study conducted in China to evaluate the treatment of advanced non-small cell lung cancer with JSKN016 in combination therapy. The enrolled subjects are all in the locally advanced or metastatic stage of non-small cell lung cancer.

Conditions

Interventions

DRUG

JSKN016

Administered intravenously according to protocol.

DRUG

Carboplatin

AUC 5, Q3W, administered intravenously according to protocol.

DRUG

Furmonertinib Mesylate

160mg（cohort1A-b）or 80mg（cohort 5）, qd, administered according to protocol.

DRUG

Ivonescimab

20mg/kg, Q3W, administered intravenously according to protocol.

DRUG

Docetaxel

60mg/m\^2, Q3W, administered intravenously according to protocol.

DRUG

Tislelizumab

200mg, Q3W, administered intravenously according to protocol.

DRUG

Pembrolizumab

200mg, Q3W, administered intravenously according to protocol.

Sponsors & Collaborators

  • Jiangsu Alphamab Biopharmaceuticals Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Li Zhang · Sun Yat-sen University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-02
Primary Completion
2028-06-30
Completion
2028-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06868732 on ClinicalTrials.gov